Stem Cells, Vol 12, 23-29, Copyright © 1994 by AlphaMed Press

ORIGINAL ARTICLES

The use of animal models in cancer drug discovery and development

GA Curt
National Cancer Institute, National Institutes of Health, Bethesda, MD 20892.

The process of searching for new cancer drugs has evolved from rational empiricism using high volume murine screens towards more targeted systems designed to discover agents which are specifically active against the common solid tumors of adulthood. Irrespective of the method of discovery, animal models are necessary in cancer drug development to answer fundamental questions of drug pharmacology and end organ toxicity. This knowledge is fundamental to the design of Phase I clinical trials. Increasingly, animal models are being utilized in the earliest stages of cancer drug discovery, as well as finding new uses guiding dose escalation in man. In addition, transgenic and SCID model systems have special applicability to the preclinical and clinical development of biological agents. This article reviews the emerging roles of animal models in cancer drug discovery and development.

This article has been cited by other articles:

				T. Voskoglou-Nomikos, J. L. Pater, and L. Seymour Clinical Predictive Value of the in Vitro Cell Line, Human Xenograft, and Mouse Allograft Preclinical Cancer Models Clin. Cancer Res., September 15, 2003; 9(11): 4227 - 4239. [Abstract] [Full Text] [PDF]

				L. H. Arp Tumor Models: Assessing Toxicity in Efficacy Studies Toxicol Pathol, January 1, 1999; 27(1): 121 - 122. [Abstract] [PDF]